Page last updated: 2024-11-11

crotonic acid betaine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

crotonic acid betaine: RN given refers to inner salt without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5462194
CHEMBL ID3234369
CHEBI ID17237
CHEBI ID11946
MeSH IDM0084372

Synonyms (34)

Synonym
crotonsaeurebetain [german]
2-propen-1-aminium, 3-carboxy-n,n,n-trimethyl-, hydroxide, inner salt
ammonium, (3-carboxyallyl)trimethyl-, hydroxide, inner salt
(3-carboxyallyl)trimethylammonium hydroxide, inner salt
CHEBI:17237 ,
crotonsaeurebetain
(2e)-4-(trimethylammonio)but-2-enoate
C04114 ,
croton betaine
(e)-4-(trimethylammonio)but-2-enoate
crotonobetaine
927-89-9
CROTONO-BETAINE ,
4-(trimethylamino)but-2-enoate
(e)-4-(trimethylamino)but-2-enoate
crotonic acid betaine
4-(trimethylammonio)but-2-enoate
CHEBI:11946
(e)-4-(trimethylazaniumyl)but-2-enoate
4-(trimethylazaniumyl)but-2-enoate
AKOS006276197
CHEMBL3234369 ,
crotonylbetaine(carnitineimpurity)(rg)
bdbm50007973
crotonoylbetaine
4-trimethyl-ammonio-2-butenoate
trans-crotonobetaine
Q24644559
6778-30-9
unii-zj9sa2p3k7
2-propen-1-aminium,3-carboxy-n,n,n-trimethyl-, inner salt
2-propen-1-aminium, 3-carboxy-n,n,n-trimethyl-, inner salt, (2e)-
ZJ9SA2P3K7 ,
(e)-4-trimethylazaniumylbut-2-enoate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
4-(trimethylammonio)but-2-enoate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-butyrobetaine dioxygenaseHomo sapiens (human)IC50 (µMol)3.80000.69003.16457.9000AID1128822
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (1)

Processvia Protein(s)Taxonomy
carnitine biosynthetic processGamma-butyrobetaine dioxygenaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
iron ion bindingGamma-butyrobetaine dioxygenaseHomo sapiens (human)
protein bindingGamma-butyrobetaine dioxygenaseHomo sapiens (human)
zinc ion bindingGamma-butyrobetaine dioxygenaseHomo sapiens (human)
gamma-butyrobetaine dioxygenase activityGamma-butyrobetaine dioxygenaseHomo sapiens (human)
identical protein bindingGamma-butyrobetaine dioxygenaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
cytosolGamma-butyrobetaine dioxygenaseHomo sapiens (human)
extracellular exosomeGamma-butyrobetaine dioxygenaseHomo sapiens (human)
mitochondrionGamma-butyrobetaine dioxygenaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1128822Inhibition of human recombinant BBOX expressed in Saccharomyces cerevisiae AH22 assessed as formation of carnitine from gamma-butyrobetaine preincubated for 15 mins measured after 30 mins by UPLC-MS/MS analysis2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Targeting carnitine biosynthesis: discovery of new inhibitors against γ-butyrobetaine hydroxylase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (25.00)18.7374
1990's4 (16.67)18.2507
2000's10 (41.67)29.6817
2010's1 (4.17)24.3611
2020's3 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.51 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other24 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]